The Indian Practitioner

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Medi Matters


     

   Subscribe/Renew Journal


Researchers from the Fels Institute for Cancer Research & Molecular Biology at the Lewis Katz School of Medicine at Temple University (LKSOM), discovered that inhibiting CDK9, a DNA transcription regulator, reactivates genes that have been epigenetically silenced by cancer. Hanghang Zhang, PhD, at the Fels Institute, performed a live cell drug screen with genetic confirmation to identify CDK9 as a target and to develop and test an effective inhibitor - MC180295. As this new drug is highly selective, there are no side effects due to inhibiting the cell cycle.
Subscription Login to verify subscription
User
Notifications
Font Size


Abstract Views: 269

PDF Views: 0




  • Medi Matters

Abstract Views: 269  |  PDF Views: 0

Authors

Abstract


Researchers from the Fels Institute for Cancer Research & Molecular Biology at the Lewis Katz School of Medicine at Temple University (LKSOM), discovered that inhibiting CDK9, a DNA transcription regulator, reactivates genes that have been epigenetically silenced by cancer. Hanghang Zhang, PhD, at the Fels Institute, performed a live cell drug screen with genetic confirmation to identify CDK9 as a target and to develop and test an effective inhibitor - MC180295. As this new drug is highly selective, there are no side effects due to inhibiting the cell cycle.